1
|
Tompkins LH, Prina SR, Gellman BN, Morello GF, Roussel T, Kopechek JA, Williams SJ, Petit PC, Slaughter MS, Koenig SC, Dasse KA. Development of Inspired Therapeutics Pediatric VAD: Benchtop Evaluation of Impeller Performance and Torques for MagLev Motor Design. Cardiovasc Eng Technol 2022; 13:307-317. [PMID: 34518953 PMCID: PMC8918059 DOI: 10.1007/s13239-021-00578-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 08/22/2021] [Indexed: 12/01/2022]
Abstract
PURPOSE Despite the availability of first-generation extracorporeal mechanical circulatory support (MCS) systems that are widely used throughout the world, there is a need for the next generation of smaller, more portable devices (designed without cables and a minimal number of connectors) that can be used in all in-hospital and transport settings to support patients in heart failure. Moreover, a system that can be universally used for all indications for use including cardiopulmonary bypass (CPB), uni- or biventricular support (VAD), extracorporeal membrane oxygenation (ECMO) and respiratory assist that is suitable for use for adult, neonate, and pediatric patients is desirable. Providing a single, well designed, universal technology could reduce the incidence of human errors by limiting the need for training of hospital staff on a single system for a variety of indications throughout the hospital rather than having to train on multiple complex systems. The objective of this manuscript is to describe preliminary research to develop the first prototype pump for use as a ventricular assist device for pediatric patients with the Inspired Universal MCS technology. The Inspired VAD Universal System is an innovative extracorporeal blood pumping system utilizing novel MagLev technology in a single portable integrated motor/controller unit which can power a variety of different disposable pump modules intended for neonate, pediatric, and adult ventricular and respiratory assistance. METHODS A prototype of the Inspired Pediatric VAD was constructed to determine the hemodynamic requirements for pediatric applications. The magnitude/range of hydraulic torque of the internal impeller was quantified. The hydrodynamic performance of the prototype pump was benchmarked using a static mock flow loop model containing a heated blood analogue solution to test the pump over a range of rotational speeds (500-6000 RPM), flow rates (0-3.5 L/min), and pressures (0 to ~ 420 mmHg). The device was initially powered by a shaft-driven DC motor in lieu of a full MagLev design, which was also used to calculate the fluid torque acting on the impeller. RESULTS The pediatric VAD produced flows as high as 4.27 L/min against a pressure of 127 mmHg at 6000 RPM and the generated pressure and flow values fell within the desired design specifications. CONCLUSIONS The empirically determined performance and torque values establish the requirements for the magnetically levitated motor design to be used in the Inspired Universal MagLev System. This next step in our research and development is to fabricate a fully integrated and functional magnetically levitated pump, motor and controller system that meets the product requirement specifications and achieves a state of readiness for acute ovine animal studies to verify safety and performance of the system.
Collapse
Affiliation(s)
- Landon H Tompkins
- Department of Bioengineering, University of Louisville, Louisville, KY, 40202, USA
| | | | - Barry N Gellman
- Inspired Therapeutics LLC, 125 E. Merritt Island Cswy, #107-341, Merritt Island, FL, 32925, USA
| | | | - Thomas Roussel
- Department of Bioengineering, University of Louisville, Louisville, KY, 40202, USA
| | - Jonathan A Kopechek
- Department of Bioengineering, University of Louisville, Louisville, KY, 40202, USA
| | - Stuart J Williams
- Department of Mechanical Engineering, University of Louisville, Louisville, KY, 40202, USA
| | - Priscilla C Petit
- Inspired Therapeutics LLC, 125 E. Merritt Island Cswy, #107-341, Merritt Island, FL, 32925, USA
| | - Mark S Slaughter
- Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 40202, USA
| | - Steven C Koenig
- Departments of Bioengineering and CT Surgery, Cardiovascular Innovation Institute, University of Louisville, 302 East Muhammad Ali Blvd, Room 408, Louisville, KY, 40202, USA.
| | - Kurt A Dasse
- Inspired Therapeutics LLC, 125 E. Merritt Island Cswy, #107-341, Merritt Island, FL, 32925, USA.
- Departments of Bioengineering and CT Surgery, Cardiovascular Innovation Institute, University of Louisville, 302 East Muhammad Ali Blvd, Room 408, Louisville, KY, 40202, USA.
| |
Collapse
|
2
|
Tompkins LH, Gellman BN, Morello GF, Prina SR, Roussel T, Kopechek JA, Petit PC, Slaughter MS, Koenig SC, Dasse KA. Design and Computational Evaluation of a Pediatric MagLev Rotary Blood Pump. ASAIO J 2021; 67:1026-1035. [PMID: 33315663 PMCID: PMC8187468 DOI: 10.1097/mat.0000000000001323] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Pediatric heart failure (HF) patients have been a historically underserved population for mechanical circulatory support (MCS) therapy. To address this clinical need, we are developing a low cost, universal magnetically levitated extracorporeal system with interchangeable pump heads for pediatric support. Two impeller and pump designs (pump V1 and V2) for the pediatric pump were developed using dimensional analysis techniques and classic pump theory based on defined performance criteria (generated flow, pressure, and impeller diameter). The designs were virtually constructed using computer-aided design (CAD) software and 3D flow and pressure features were analyzed using computational fluid dynamics (CFD) analysis. Simulated pump designs (V1, V2) were operated at higher rotational speeds (~5,000 revolutions per minute [RPM]) than initially estimated (4,255 RPM) to achieve the desired operational point (3.5 L/min flow at 150 mm Hg). Pump V2 outperformed V1 by generating approximately 30% higher pressures at all simulated rotational speeds and at 5% lower priming volume. Simulated hydrodynamic performance (achieved flow and pressure, hydraulic efficiency) of our pediatric pump design, featuring reduced impeller size and priming volume, compares favorably to current commercially available MCS devices.
Collapse
Affiliation(s)
- Landon H. Tompkins
- Department of Bioengineering, University of Louisville, Louisville, KY 40202
| | | | | | | | - Thomas Roussel
- Department of Bioengineering, University of Louisville, Louisville, KY 40202
| | | | | | - Mark S. Slaughter
- Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY 40202
| | - Steven C. Koenig
- Department of Bioengineering, University of Louisville, Louisville, KY 40202
- Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY 40202
| | - Kurt A. Dasse
- Department of Bioengineering, University of Louisville, Louisville, KY 40202
- Inspired Therapeutics LLC, Merritt Island, FL 32925
- Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY 40202
| |
Collapse
|
3
|
Petit PC, Fine DH, Vásquez GB, Gamero L, Slaughter MS, Dasse KA. The Pathophysiology of Nitrogen Dioxide During Inhaled Nitric Oxide Therapy. ASAIO J 2017; 63:7-13. [PMID: 27556146 DOI: 10.1097/mat.0000000000000425] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Administration of inhaled nitric oxide (NO) with the existing compressed gas delivery systems is associated with unavoidable codelivery of nitrogen dioxide (NO2), an unwanted toxic contaminant that forms when mixed with oxygen. The NO2 is generated when NO is diluted with O2-enriched air before delivery to the patient. When NO2 is inhaled by the patient, it oxidizes protective antioxidants within the epithelial lining fluid (ELF) and triggers extracellular damage in the airways. The reaction of NO2 within the ELF triggers oxidative stress (OS), possibly leading to edema, bronchoconstriction, and a reduced forced expiratory volume in 1 second. Nitrogen dioxide has been shown to have deleterious effects on the airways of high-risk patients including neonates, patients with respiratory and heart failure, and the elderly. Minimizing co-delivery of NO2 for the next generation delivery systems will be a necessity to fully optimize the pulmonary perfusion of NO because of vasodilation, whereas minimizing the negative ventilatory and histopathological effects of NO2 exposure during inhaled NO therapy.
Collapse
Affiliation(s)
- Priscilla C Petit
- From the *Biomedical Research, GeNO LLC, Cocoa, Florida; and †Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky
| | | | | | | | | | | |
Collapse
|
4
|
Maul TM, Kocyildirim E, Marks JD, Bengston SG, Olia SE, Callahan PM, Kameneva MV, Franklin S, Borovetz HS, Dasse KA, Wearden PD. Pre-clinical Implants of the Levitronix PediVAS ® Pediatric Ventricular Assist Device - Strategy for Regulatory Approval. Cardiovasc Eng Technol 2011; 2:263-275. [PMID: 23494160 PMCID: PMC3594505 DOI: 10.1007/s13239-011-0063-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The PediVAS blood pump is a magnetically levitated centrifugal pump designed for pediatric bridge-to-decision or bridge-to-recovery in pediatric patients from 3-20kg in weight. In preparation for submission of an investigational device exemption (IDE) application, we completed a final six-animal series of pre-clinical studies. The studies were conducted under controlled conditions as prescribed by the recently released FDA guidance document for animal studies for cardiovascular devices. Three 30-day chronic left ventricular support studies were completed in a juvenile lamb model to demonstrate the safety and hemocompatibility of the PediVAS pump. Three additional 8-hour acute biventricular support studies were performed to demonstrate the feasibility of this approach from a hemodynamic and systems standpoint. It is estimated that 50% of pediatric patients who require left ventricular support also require right ventricular support. All studies were successfully completed without complications, device malfunctions, or adverse events. End-organ function was normal for the chronic studies. We noted small surface lesions on one kidney from each chronic study as well as the presence of ring thrombus on connectors, as expected for these types of studies in animal models. The strategy and challenges imposed by performing a controlled cardiovascular device study in a juvenile lamb model are discussed. We believe that these successful implants demonstrate safety and performance for the PediVAS device for support of an IDE application to initiate human clinical trials and provide a roadmap for other researchers.
Collapse
|
5
|
Wu ZJ, Gellman B, Zhang T, Taskin ME, Dasse KA, Griffith BP. Computational Fluid Dynamics and Experimental Characterization of the Pediatric Pump-Lung. Cardiovasc Eng Technol 2011; 2:276-287. [PMID: 24839468 DOI: 10.1007/s13239-011-0071-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The pediatric pump-lung (PediPL) is a miniaturized integrated pediatric pump-oxygenator specifically designed for cardiac or cardiopulmonary support for patients weighing 5-20 kg to allow mobility and extended use for 30 days. The PediPL incorporates a magnetically levitated impeller with uniquely configured hollow fiber membranes into a single unit capable of performing both pumping and gas exchange. A combined computational and experimental study was conducted to characterize the functional and hemocompatibility performances of this newly developed device. The three-dimensional flow features of the PediPL and its hemolytic characteristics were analyzed using computational fluid dynamics based modeling. The oxygen exchange was modeled based on a convection-diffusion-reaction process. The hollow fiber membranes were modeled as a porous medium which incorporates the flow resistance in the bundle by an added momentum sink term. The pumping function was evaluated for the required range of operating conditions (0.5-2.5 L/min and 1000-3000 rpm). The blood damage potentials were further analyzed in terms of flow and shear stress fields, and the calculations of hemolysis index. In parallel, the hydraulic pump performance, oxygen transfer and hemolysis level were quantified experimentally. Based on the computational and experimental results, the PediPL device is found to be functional to provide necessary oxygen transfer and blood pumping requirements for the pediatric patients. Smooth blood flow characteristics and low blood damage potential were observed in the entire device. The in-vitro tests further confirmed that the PediPL can provide adequate blood pumping and oxygen transfer over the range of intended operating conditions with acceptable hemolytic performance. The rated flow rate for oxygenation is 2.5 L/min. The normalized index of hemolysis is 0.065 g/100L at 1.0 L/min and 3000 rpm.
Collapse
Affiliation(s)
- Zhongjun J Wu
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | - Tao Zhang
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - M Ertan Taskin
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | - Bartley P Griffith
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| |
Collapse
|
6
|
Taskin ME, Fraser KH, Zhang T, Gellman B, Fleischli A, Dasse KA, Griffith BP, Wu ZJ. Computational characterization of flow and hemolytic performance of the UltraMag blood pump for circulatory support. Artif Organs 2011; 34:1099-113. [PMID: 20626739 DOI: 10.1111/j.1525-1594.2010.01017.x] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The Levitronix UltraMag blood pump is a next generation, magnetically suspended centrifugal pump and is designed to provide circulatory support for pediatric and adult patients. The aim of this study is to investigate the hemodynamic and hemolytic characteristics of this pump using the computational fluid dynamics (CFD) approach. The computational domain for CFD analysis was constructed from the three-dimensional geometry (3D) of the UltraMag blood pump and meshed into 3D tetrahedral/hybrid elements. The governing equations of fluid flow were computationally solved to obtain a blood flow through the blood pump. Further, hemolytic blood damage was calculated by solving a scalar transport equation where the scalar variable and the source term were obtained utilizing an empirical power-law correlation between the fluid dynamic variables and hemolysis. To obtain mesh independent flow solution, a comparative examination of vector fields, hydrodynamic performance, and hemolysis predictions were carried out. Different sizes of tetrahedral and tetrahedral/hexahedral mixed hybrid models were considered. The mesh independent solutions were obtained by a hybrid model. Laminar and SST κ-ω turbulence flow models were used for different operating conditions. In order to pinpoint the most significant hemolytic region, the flow field analysis was coupled to the hemolysis predictions. In summary, computational characterization of the device was satisfactorily carried out within the targeted operating conditions of the device, and it was observed that the UltraMag blood pump can be safely operated for its intended use to create a circulatory support for both pediatric and adult-sized patients.
Collapse
Affiliation(s)
- M Ertan Taskin
- Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
Zhang J, Taskin ME, Koert A, Zhang T, Gellman B, Dasse KA, Gilbert RJ, Griffith BP, Wu ZJ. Computational Design and In Vitro Characterization of an Integrated Maglev Pump-Oxygenator. Artif Organs 2009; 33:805-17. [DOI: 10.1111/j.1525-1594.2009.00807.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Zhang T, Cheng G, Koert A, Zhang J, Gellman B, Yankey GK, Satpute A, Dasse KA, Gilbert RJ, Griffith BP, Wu ZJ. Functional and biocompatibility performances of an integrated Maglev pump-oxygenator. Artif Organs 2009; 33:36-45. [PMID: 19178439 DOI: 10.1111/j.1525-1594.2008.00672.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
To provide respiratory support for patients with lung failure, a novel compact integrated pump-oxygenator is being developed. The functional and biocompatibility performances of this device are presented. The pump-oxygenator is designed by combining a magnetically levitated pump/rotor with a uniquely configured hollow fiber membrane bundle to create an assembly free, ultracompact, all-in-one system. The hemodynamics, gas transfer and biocompatibility performances of this novel device were investigated both in vitro in a circulatory flow loop and in vivo in an ovine animal model. The in vitro results showed that the device was able to pump blood flow from 2 to 8 L/min against a wide range of pressures and to deliver an oxygen transfer rate more than 300 mL/min at a blood flow of 6 L/min. Blood damage tests demonstrated low hemolysis (normalized index of hemolysis [NIH] approximately 0.04) at a flow rate of 5 L/min against a 100-mm Hg afterload. The data from five animal experiments (4 h to 7 days) demonstrated that the device could bring the venous blood to near fully oxygen-saturated condition (98.6% +/- 1.3%). The highest oxygen transfer rate reached 386 mL/min. The gas transfer performance was stable over the study duration for three 7-day animals. There was no indication of blood damage. The plasma free hemoglobin and platelet count were within the normal ranges. No gross thrombus is found on the explanted pump components and fiber surfaces. Both in vitro and in vivo results demonstrated that the newly developed pump-oxygenator can achieve sufficient blood flow and oxygen transfer with excellent biocompatibility.
Collapse
Affiliation(s)
- Tao Zhang
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
The development of microfluidic devices supporting physiological blood flow has the potential to yield biomedical technologies emulating human organ function. However, advances in this area have been constrained by the fact that artificial microchannels constructed for such devices need to achieve maximum chemical diffusion as well as hemocompatibility. To address this issue, we designed an elastomeric microfluidic flow device composed of poly (dimethylsiloxane) to emulate the geometry and flow properties of the pulmonary microcirculation. Our chip design is characterized by high aspect ratio (width > height) channels in an orthogonally interconnected configuration. Finite element simulations of blood flow through the network design chip demonstrated that the apparent pressure drop varied in a linear manner with flow rate. For simulated flow rates <250 mul min, the simulated pressure drop was <2000 Pa, the flow was laminar, and hemolysis was minimal. Hemolysis rate, assayed in terms of [total plasma hemoglobin (TPH) (sample - control)/(TPH control)] during 6 and 12 hour perfusions at 250 mul/min, was <5.0% through the entire period of device perfusion. There was no evidence of microscopic thrombus at any channel segment or junction under these perfusion conditions. We conclude that a microfluidic blood flow device possessing asymmetric and interconnected microchannels exhibits uniform flow properties and preliminary hemocompatibility. Such technology should foster the development of miniature oxygenators and similar biomedical devices requiring both a microscale reaction volume and physiological blood flow.
Collapse
Affiliation(s)
- Richard J Gilbert
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02135, USA
| | | | | | | | | | | | | |
Collapse
|
11
|
Tuzun E, Harms K, Liu D, Dasse KA, Conger JL, Richardson JS, Fleischli A, Frazier OH, Radovancevic B. Preclinical Testing of the Levitronix Ultramag Pediatric Cardiac Assist Device in a Lamb Model. ASAIO J 2007; 53:392-6. [PMID: 17515735 DOI: 10.1097/mat.0b013e3180340974] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
We evaluated the effects of the Levitronix UltraMag pediatric ventricular assist system on healthy animals during 29- to 90-day periods by assessing hemocompatibility and hepatic and renal functions while operating the device in a flow range suitable for pediatric patients. Nine lambs (weight, 15 to 24 kg) received the Levitronix UltraMag with an outflow cannula anastomosed to the descending aorta and an inflow cannula inserted into the left ventricular apex. Pump function data were collected at 1-hour intervals, and postoperative hematology and clinical chemistry tests were performed weekly throughout the study. Complete necropsy and histopathologic examinations were performed at study termination. Pump and circuit were thoroughly inspected for evidence of thrombi. All animals reached the scheduled endpoint of 29 to 90 days without device-related problems. Mean flow was maintained at 1.14 +/- 0.19 L/min. Hematologic values were within normal range in all animals except in one lamb that had a severe hemolytic reaction after cefazolin sodium administration. In all animals, serum glutamic-oxaloacetic transaminase and creatinine kinase levels increased after surgery but gradually returned to normal limits within 1 week. Postmortem examination of the explanted organs revealed small infarcted areas in five lamb kidneys, but renal function was unaffected. All other major organs were unremarkable. In one explanted pump (a 30-day study), a small thrombus was seen within the impeller blade. The other eight pumps were free of thrombus. The Levitronix UltraMag successfully operated in pediatric flow ranges without device-related adverse events.
Collapse
Affiliation(s)
- Egemen Tuzun
- Cardiovascular Surgical Research Laboratories, Texas Heart Institute, Houston, TX, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Zhang J, Koert A, Gellman B, Gempp TM, Dasse KA, Gilbert RJ, Griffith BP, Wu ZJ. Optimization of a miniature Maglev ventricular assist device for pediatric circulatory support. ASAIO J 2007; 53:23-31. [PMID: 17237645 DOI: 10.1097/01.mat.0000247043.18115.f7] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
A miniature Maglev blood pump based on magnetically levitated bearingless technology is being developed and optimized for pediatric patients. We performed impeller optimization by characterizing the hemodynamic and hemocompatibility performances using a combined computational and experimental approach. Both three-dimensional flow features and hemolytic characteristics were analyzed using computational fluid dynamics (CFD) modeling. Hydraulic pump performances and hemolysis levels of three different impeller designs were quantified and compared numerically. Two pump prototypes were constructed from the two impeller designs and experimentally tested. Comparison of CFD predictions with experimental results showed good agreement. The optimized impeller remarkably increased overall pump hydraulic output by more than 50% over the initial design. The CFD simulation demonstrated a clean and streamlined flow field in the main flow path. The numerical results by hemolysis model indicated no significant high shear stress regions. Through the use of CFD analysis and bench-top testing, the small pediatric pump was optimized to achieve a low level of blood damage and improved hydraulic performance and efficiency. The Maglev pediatric blood pump is innovative due to its small size, very low priming volume, excellent hemodynamic and hematologic performance, and elimination of seal-related and bearing-related failures due to adoption of magnetically levitated bearingless motor technology, making it ideal for pediatric applications.
Collapse
Affiliation(s)
- Juntao Zhang
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Zhang J, Gellman B, Koert A, Dasse KA, Gilbert RJ, Griffith BP, Wu ZJ. Computational and experimental evaluation of the fluid dynamics and hemocompatibility of the CentriMag blood pump. Artif Organs 2006; 30:168-77. [PMID: 16480391 DOI: 10.1111/j.1525-1594.2006.00203.x] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The CentriMag centrifugal blood pump is a newly developed ventricular assist device based on magnetically levitated bearingless rotor technology. A combined computational and experimental study was conducted to characterize the hemodynamic and hemocompatibility performances of this novel blood pump. Both the three-dimensional flow features of the CentriMag blood pump and its hemolytic characteristics were analyzed using computational fluid dynamics (CFD)-based modeling. The hydraulic pump performance and hemolysis level were quantified experimentally. The CFD simulation demonstrated a clean and streamlined flow field in the main components of the CentriMag blood pump. The predicted results by hemolysis model indicated no significant high shear stress regions in the pump. A comparison of CFD predictions and experimental results showed good agreements. The relatively large gap passages (1.5 mm) between the outer rotor walls and the lower housing cavity walls provide a very good surface washing through a secondary flow path while the shear stresses in the secondary flow paths are reduced, resulting in a low rate of hemolysis ([Normalized Index of Hemolysis] NIH = 0.0029 +/- 0.006) without a decrease of the pump's hydrodynamic performance (pressure head: 352 mm Hg at a flow rate of 5.0 L/min and a rotational speed of 4,000 rpm).
Collapse
Affiliation(s)
- Juntao Zhang
- Artificial Organs Laboratory, Department of Surgery, University of Maryland School of Medicine, Baltimore, 21201, USA
| | | | | | | | | | | | | |
Collapse
|
14
|
Monzyk BF, Burckle EC, Carleton LM, Busch J, Dasse KA, Martin PM, Gilbert RJ. Photolytically Driven Generation of Dissolved Oxygen and Increased Oxyhemoglobin in Whole Blood. ASAIO J 2006; 52:456-66. [PMID: 16883128 DOI: 10.1097/01.mat.0000219086.39192.9a] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The severely debilitating nature of chronic lung disease has long provided the impetus for the development of technologies to supplement the respiratory capacity of the human lung. Although conventional artificial lung technologies function by delivering pressurized oxygen to the blood through a system of hollow fibers or tubes, our approach uses photolytic energy to generate dissolved oxygen (DO) from the water already present in blood, thus eliminating the need for gas delivery. We have previously demonstrated that it is feasible to generate dissolved oxygen from water based on UVA illumination of a highly absorbent TiO2 thin film. In the current study, we extend this work by using photolytic energy to generate DO from whole blood, thus resulting in an increase of oxyhemoglobin as a function of back side TiO2 surface film illumination. Initial experiments, performed with Locke's Ringer solution, demonstrated effective film thickness and material selection for the conductive layer. The application of a small bias voltage was used to conduct photogenerated electrons from the aqueous phase to minimize electron recombination with the DO.Mixed arterial-venous bovine blood was flowed in a recirculating loop over TiO2 nanocrystalline films illuminated on the side opposite the blood (or "back side") to eliminate the possibility of any direct exposure of blood to light. After light exposure of the TiO2 film, the fraction of oxyhemoglobin in the blood rapidly increased to near saturation and remained stable throughout the trial period. Last, we evaluated potential biofouling of the DO generating surface by scanning electron microscopy, after photolytically energized DO generation in whole blood, and observed no white or red blood cell surface deposition, nor the accumulation of any other material at this magnification. We conclude that it is feasible to photolytically oxygenate the hemoglobin contained in whole blood with oxygen derived from the blood's own water content without involving a gaseous phase.
Collapse
|
15
|
Abstract
There is an established need for pulmonary technology capable of facilitated gas exchange in the blood, thereby bypassing the alveolar-capillary interface. To address this need, we emulated one of the best-known photolytic reactions in nature, photosynthesis, in which green plants use sunlight to drive the exchange of oxygen for carbon dioxide. Our goal in the current study was to demonstrate the feasibility of direct photolytic conversion of water to liquid phase oxygen (dissolved oxygen [DO]) in synthetic serum. To this end, we constructed a test flow cell consisting of a conductive coating of vacuum-deposited titanium (Ti) metal, adherent TiO2 (anatase), and MnO2, applied as a laminate to a glass substrate, and then immersed the device in Locke's-Ringer solution (synthetic blood serum). Long wavelength (low energy) ultraviolet A laser light, directed to the transparent glass slide, reproducibly resulted in the generation of an active form of oxygen (AO), which was subsequently converted directly by the catalytic action of MnO2 to DO. The absence of light activation provided an entirely null response. We conclude that the photolytic production of DO from water in a blood serum surrogate, with commensurate CO2 clearance, is feasible. A prototype photolytic module is proposed, which uses multiple parallel photolytic surfaces to improve system production capacity and CO2 clearance through selective gas-liquid separation from the oxygen-enriched fluid.
Collapse
|
16
|
Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001; 122:1186-95. [PMID: 11726895 DOI: 10.1067/mtc.2001.118274] [Citation(s) in RCA: 443] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Despite advances in heart transplantation and mechanical circulatory support, mortality among transplant candidates remains high. Better ways are needed to ensure the survival of transplant candidates both inside and outside the hospital. METHODS In a prospective, multicenter clinical trial conducted at 24 centers in the United States, 280 transplant candidates (232 men, 48 women; median age, 55 years; range, 11-72 years) unresponsive to inotropic drugs, intra-aortic balloon counterpulsation, or both, were treated with the HeartMate Vented Electric Left Ventricular Assist System (VE LVAS). A cohort of 48 patients (40 men, 8 women; median age, 50 years; range, 21-67 years) not supported with an LVAS served as a historical control group. Outcomes were measured in terms of laboratory data (hemodynamic, hematologic, and biochemical), adverse events, New York Heart Association functional class, and survival. RESULTS The VE LVAS-treated and non-VE LVAS-treated (control) groups were similar in terms of age, sex, and distribution of patients by diagnosis (ischemic cardiomyopathy, idiopathic cardiomyopathy, and subacute myocardial infarction). VE LVAS support lasted an average of 112 days (range, < 1-691 days), with 54 patients supported for > 180 days. Mean VE LVAS flow (expressed as pump index) throughout support was 2.8 L x min(-1) x m(-2). Median total bilirubin values decreased from 1.2 mg/dL at baseline to 0.7 mg/dL (P =.0001); median creatinine values decreased from 1.5 mg/dL at baseline to 1.1 mg/dL (P =.0001). VE LVAS-related adverse events included bleeding in 31 patients (11%), infection in 113 (40%), neurologic dysfunction in 14 (5%), and thromboembolic events in 17 (6%). A total of 160 (58%) patients were enrolled in a hospital release program. Twenty-nine percent of the VE LVAS-treated patients (82/280) died before receiving a transplant, compared with 67% of controls (32/48) (P <.001). Conversely, 71% of the VE LVAS-treated patients (198/280) survived: 67% (188/280) ultimately received a heart transplant, and 4% (10/280) had the device removed electively. One-year post-transplant survival of VE LVAS-treated patients was significantly better than that of controls (84% [158/188] vs 63% [10/16]; log rank analysis P =.0197). CONCLUSION The HeartMate VE LVAS provides adequate hemodynamic support, has an acceptably low incidence of adverse effects, and improves survival in heart transplant candidates both inside and outside the hospital. The studies of the HeartMate LVAS (both pneumatic and electric) for Food and Drug Administration approval are the only studies with a valid control group to show a survival benefit for cardiac transplantation.
Collapse
Affiliation(s)
- O H Frazier
- Department of Cardiovascular Research, Texas Heart Institute, Houston, Tex 77225-0345, USA.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
BACKGROUND Safe transition from cardiopulmonary bypass to the HeartMate left ventricular assist device without periods of low output, air emboli, or injury to the right ventricle is vital to its successful implantation. A right atrial-to-left ventricular shunt has been developed to purge quickly and completely all air from the system and prevent its reentry, as well as to assist the right ventricle during the transition from cardiopulmonary bypass to the HeartMate. METHODS From January 1994 through July 1996, we used an extracorporeal membrane oxygenation right atrial-to-left ventricular shunt during 17 HeartMate implantations in 16 patients. The shunt consists of the existing right atrial two-stage cannula, the bypass circuit, and a separate aortic line that fills the left ventricle using a 21F cannula in the lateral ventricular wall. Air is monitored in the heart and aorta using transesophageal echocardiography. RESULTS Ten of the 16 patients are living and 8 have undergone transplantation. Two patients are still using the device and are awaiting transplantation. None of the patients have experienced postoperative neurologic events suggestive of air emboli. CONCLUSIONS The extracorporeal membrane oxygenation right atrial-to-left ventricular shunt is simple and inexpensive to construct. It provides for a smoother and safer transition from cardiopulmonary bypass to the HeartMate left ventricular assist device.
Collapse
Affiliation(s)
- A J Tector
- Infinity Heart Institute, St Luke's Medical Center, Milwaukee, Wisconsin, USA
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
To examine the relationship between age and outcome after implantable left ventricular assist system support, the authors investigated the results of 223 patients from 17 centers who were supported with a HeartMate (Thermo Cardiosystems, Inc., Woburn, MA) pneumatic left ventricular assist system between 1986 and 1994. In addition, the authors examined a single center's experience with 67 patients between 1992 and 1996. Ages are separated by decile and ranged from 10 to 69 years. Men dominated all age groups, averaging 82% of the total (range, 64-91%). Viral, idiopathic, and post partum cardiomyopathies were the indication for support in 88% of the patients younger than 39 years of age. Ischemic cardiomyopathy was the cause of myocardial failure in the majority of patients older than 40 years of age (40-49 years, 54%; 50-59 years, 57%; and 60-69 years, 67%). Patients aged 40-59 accounted for 64% of the patients supported, and had the best outcomes both on support and after transplantation. Survival to transplantation was not significantly different among the groups, although the patients older than 60 and younger than 69 years of age had higher mortalities on support, most commonly from cardiac failure. At the Cleveland Clinic Foundation, the survival to transplantation and survival to discharge were indistinguishable between age groups. Age does not appear to be significant risk factor for outcome after implantable left ventricular assist system support. These results predict acceptable mortality for patients supported who are older than the age of 60.
Collapse
Affiliation(s)
- N G Smedira
- Cleveland Clinic Foundation, Department of Thoracic and Cardiovascular Surgery, OH 44195, USA
| | | | | | | | | | | |
Collapse
|
19
|
Frazier OH, Rose EA, McCarthy P, Burton NA, Tector A, Levin H, Kayne HL, Poirier VL, Dasse KA. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995; 222:327-36; discussion 336-8. [PMID: 7677462 PMCID: PMC1234813 DOI: 10.1097/00000658-199509000-00010] [Citation(s) in RCA: 265] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE This nonrandomized study using concurrent controls was performed to determine whether the HeartMate implantable pneumatic (IP) left ventricular assist system (LVAS) could provide sufficient hemodynamic support to allow rehabilitation of severely debilitated transplant candidates and to evaluate whether such support reduced mortality before and after transplantation. METHODS Outcomes of 75 LVAS patients were compared with outcomes of 33 control patients (not treated with an LVAS) at 17 centers in the United States. All patients were transplant candidates who met the following hemodynamic criteria: pulmonary capillary wedge pressure > or = 20 mm Hg with a systolic blood pressure < or = 80 mm Hg or a cardiac index < or = 2.0 L/minute/m2. In addition, none of the patients met predetermined exclusion criteria. RESULTS More LVAS patients than control patients survived to transplantation: 53 (71%) versus 12 (36%) (p = 0.001); and more LVAS patients were alive at 1 year: 48 (91%) versus 8 (67%) (p = 0.0001). The time to transplantation was longer in the group supported with the LVAS (average, 76 days; range, < 1-344 days) than in the control group (average, 12 days; range, 1-72 days). In the LVAS group, the average pump index (2.77 L/minute/m2) throughout support was 50% greater than the corresponding cardiac index (1.86 L/minute/m2) at implantation (p = 0.0001). In addition, 58% of LVAS patients with renal dysfunction survived, compared with 16% of the control patients (p < 0.001). CONCLUSIONS The LVAS provided adequate hemodynamic support and was effective in rehabilitating patients based on improved renal, hepatic, and physical capacity assessments over time. In the LVAS group, pretransplant mortality decreased by 55%, and the probability of surviving 1 year after transplant was significantly greater than in the control group (90% vs. 67%, p = 0.03). Thus, the HeartMate IP LVAS proved safe and effective as a bridge to transplant and decreased the risk of death for patients waiting for transplantation.
Collapse
Affiliation(s)
- O H Frazier
- Department of Cardiovascular Research, Texas Heart Institute, Houston, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Jaski BE, Branch KR, Dasse KA, Dembitsky WP. Diagnosis and treatment of complications in patients implanted with a TCI left ventricular assist device. J Interv Cardiol 1995; 8:275-82. [PMID: 10155239 DOI: 10.1111/j.1540-8183.1995.tb00545.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Currently used left ventricular assist devices allow chronic mechanical cardiac support in the patient with end-stage heart failure. Recognition and treatment of problems uniquely associated with this device may be increasingly important for the invasive cardiologist as application of this technology becomes more prevalent.
Collapse
Affiliation(s)
- B E Jaski
- San Diego Cardiac Center, Donald M. Sharp Memorial Hospital, CA 92123, USA
| | | | | | | |
Collapse
|
21
|
Menconi MJ, Pockwinse S, Owen TA, Dasse KA, Stein GS, Lian JB. Properties of blood-contacting surfaces of clinically implanted cardiac assist devices: gene expression, matrix composition, and ultrastructural characterization of cellular linings. J Cell Biochem 1995; 57:557-73. [PMID: 7768989 DOI: 10.1002/jcb.240570320] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The development of implantable cardiac assist devices for prolonged circulatory support has been impeded by the problem of excessive thrombogenesis on the blood-prosthetic interface, with subsequent embolization. To overcome this obstacle, a ventricular assist device has been developed with textured blood-contacting surfaces to encourage the formation of a tightly adherent, hemocompatible, biological lining. In this study, we applied molecular biological techniques, in conjunction with conventional ultrastructural and biochemical techniques, to characterize the biological linings associated with the blood-contacting surfaces of 11 of these devices, which had been clinically implanted for durations ranging from 21 to 324 days. No clinical thromboembolic events or pump-related thromboembolism occurred. Biological linings developed on the textured surfaces composed of patches of cellular tissue intermingled with areas of compact fibrinous material. In addition, islands of collagenous tissue containing fibroblast-like cells appeared after 30 days of implantation. Many of these cells contained microfilaments with dense bodies indicative of myofibroblasts. RNA hybridization analyses demonstrated that the colonizing cells actively expressed genes encoding proteins for cell proliferation (histones), adhesion (fibronectin), cytoskeleton (actin, vimentin) and extracellular matrix (types I and III collagen). Linings, which never exceeded 150 microns in thickness, remained free of pathological calcification. Textured blood-contacting surfaces induced the formation of a thin, tightly adherent, viable lining which exhibited excellent long-term hemocompatibility.
Collapse
Affiliation(s)
- M J Menconi
- Department of Cell Biology, University of Massachusetts Medical School, Worcester 01655-0106, USA
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
The vented electric Heartmate LVAD (VE-LVAD) (Thermo Cardiosystems, Inc., Woburn, MA) is a reliable, fully portable system that allows selected patients with end-stage cardiomyopathy to undergo outpatient treatment while waiting for heart transplantation. This implantable, pusher-plate LVAD is actuated by an electric motor located within the pump housing. The patient wears external batteries and a system controller, which power and control the LVAD motor through a percutaneous lead. Since May 1991, four men have been supported with the VE-LVAD. They ranged in age from 33 to 50 years (mean, 44.3 years); two had idiopathic cardiomyopathy, and two had ischemic cardiomyopathy. Of the four patients, three underwent support of 196, 219, and 504 days; support in the fourth patient is ongoing at more than 90 days. All four patients were fully rehabilitated to New York Heart Association Class I status. Because they were well and fully mobile, the protocol was amended to allow these patients to leave the hospital in a four phase program that begins with 16 hr day passes and leads to hospital discharge. When patients leave the hospital, they are accompanied by trained family members or friends. The patients who have participated in the program have performed routine activities, attended social events, and spent the night at home. The VE-LVAD system seems safe and appropriate for the outpatient setting in selected patients. Patients have been able to manage the system without assistance from medical or engineering personnel. This initial positive experience with outpatient LVAD treatment demonstrates the potential for providing long-term cardiac support with this type of implantable technology.
Collapse
Affiliation(s)
- T J Myers
- Cullen Cardiovascular Research Laboratories, Texas Heart Institute, Houston 77225-0345, USA
| | | | | | | | | | | |
Collapse
|
23
|
Dasse KA, Frazier OH, Lesniak JM, Myers T, Burnett CM, Poirier VL. Clinical responses to ventricular assistance versus transplantation in a series of bridge to transplant patients. ASAIO J 1992; 38:M622-6. [PMID: 1457935 DOI: 10.1097/00002480-199207000-00111] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Hemodynamic and peripheral organ responses to ventricular assistance were compared with transplantation in a cohort of patients bridged with the HeartMate 1000 IP left ventricular assist device (LVAD) (Thermo Cardiosystems Inc., Woburn, MA). The study population included 27 patients that were supported an average of 102 days (range, 15-324 days). Two hepatic (total bilirubin and serum glutamic oxaloacetic transaminase [SGOT]) and two renal (creatinine and blood urea nitrogen [BUN]) parameters were measured: 1) before LVAD insertion, 2) 30 and 60 days during ventricular assistance, 3) before transplantation while still on the VAD, and 4) 30 and 60 days after transplantation. Total bilirubin values were significantly greater just before LVAD implant (2.3 mg/dl) than before transplantation (0.7 mg/dl). Although there was no difference after 30 days of either treatment, the total bilirubin values were greater at 60 days after transplantation (1.1 mg/dl) than at an equivalent time on the LVAD (0.6 mg/dl). The SGOT values were also significantly reduced before transplantation. No differences at 30 and 60 days after either procedure were noticed. Creatinine and BUN values were greater before LVAD implant (1.7 and 37 mg/dl) than before transplantation (1.2 and 19 mg/dl). The creatinine values were also greater after transplantation at 30 and 60 days (2.0 and 1.6 mg/dl) than at comparable intervals after LVAD implantation (1.0 and 1.2 mg/dl), presumably as a result of the use of immunosuppressive drugs. End organ function was markedly improved while on the device, enhancing the physiologic status of the patients before transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K A Dasse
- Thermo Cardiosystems, Inc., Woburn, Massachusetts 01888
| | | | | | | | | | | |
Collapse
|
24
|
Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg 1992; 53:1080-90. [PMID: 1596133 DOI: 10.1016/0003-4975(92)90393-i] [Citation(s) in RCA: 337] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The Thermo Cardiosystems Inc (Woburn, MA) HeartMate 1000 IP left ventricular assist device (LVAD) has been evaluated as a bridge to transplantation in 34 patients for up to 324 days at seven clinical centers in the United States. Sixty-five percent of the patients underwent transplantation, 80% of whom were discharged from the hospital. Six additional control patients, transplant candidates who met the entrance criteria but who did not receive the device, were also included in the study. Although 3 (50%) of the control patients received transplants, all 6 died within 77 days of having met the LVAD inclusion criteria (100% mortality). Complications resulting from use of the device were comparable with those previously reported for all ventricular assist devices, except for thromboembolic events: bleeding, 39%; infection, 25%; and right heart failure, 21%. No device-related thromboembolic events occurred, although 1 patient experienced an event related to a mechanical aortic valve in the native heart. None of the complications had a significant negative association with outcome of the patient except for right heart failure. All survivors had a significant improvement in hepatic function before transplantation. Total bilirubin values were reduced by 60% during LVAD support. No significant differences were observed when total bilirubin values were compared at 30 and 60 days after LVAD support and at 30 and 60 days after transplantation in a cohort of 15 patients (p greater than 0.05). The improvement in renal function was less predictable than that of hepatic function. Creatinine values decreased significantly before transplantation; however, the values measured at 30 and 60 days after transplantation were higher than those measured at the same intervals after LVAD support had been initiated, and this increase is presumably related to the immunosuppressive drugs. In conclusion, the HeartMate 1000 IP LVAD has been shown to be effective in supporting end-stage cardiomyopathy patients to transplantation. Thromboembolism, previously regarded as a serious complication with such devices, has not been a problem with this device. Additional patients are being enrolled into the study to further document the safety and effectiveness of this technology.
Collapse
Affiliation(s)
- O H Frazier
- Department of Cardiovascular Surgery, Texas Heart Institute, Houston 77225-0345
| | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
In order to address questions related to cell/biomaterial interactions with respect to cell function and production of extracellular matrix proteins that support or maintain cell/tissue specific properties, we have developed molecular approaches for analysis of in vivo implanted materials and in vitro studies. In an explant of a human left ventricular assist device (LVAD), intact total cellular RNA could be isolated in sufficient quantities for hybridization analyses with gene-specific probes to evaluate cell growth, cytoskeletal organization, and production of extracellular matrix proteins. Cells harvested from a 132-day implanted LVAD exhibited proliferative activity and expressed genes for fibronectin and collagen types I, III, and IV. In vitro studies revealed that endothelial cells cultured on two different segmented polyurethane biomaterials (Biomer and Tecoflex 60D) exhibited different patterns of gene expression that reflected differences in cell growth rates, morphology, and composition of the extracellular matrix. These methodologies provide a valuable approach for a detailed evaluation of: (1) the biocompatibility of cells colonizing implanted cardiac assist devices; and (2) the functionality of cells seeded onto biomaterials.
Collapse
Affiliation(s)
- M J Menconi
- Department of Cell Biology, University of Massachusetts Medical School, Worcester 01655
| | | | | | | | | |
Collapse
|
26
|
McGee MG, Myers TJ, Abou-Awdi N, Dasse KA, Radovancevic B, Lonquist JL, Duncan JM, Frazier OH. Extended support with a left ventricular assist device as a bridge to heart transplantation. ASAIO Trans 1991; 37:M425-6. [PMID: 1751220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The Heartmate-1000IP, an intracorporeal, pneumatically activated, pulsatile left ventricular assist device (LVAD) with textured blood-contacting surfaces, is undergoing clinical evaluation as a bridge to heart transplantation (HTx). During a 3 year period (January 1988 to April 1991), the authors evaluated 12 patients who required extended LVAD support (greater than 30 days) while awaiting HTx. Duration of support ranged from 31 to 233 days (mean, 117 days). LVAD performance was excellent, with average pump flow indices of 2.5-3.5 L/min/m2. Long-term antithrombotic therapy consisted of dipyridamole and aspirin in all except one patient who received only low-molecular-weight dextran. After the initial recovery period, prothrombin and partial thromboplastin times returned to baseline levels. Plasma-free hemoglobin levels averaged less than 10 mg/dl. One patient is currently receiving support (91+ days); the 11 other patients underwent successful HTx, with follow-up ranging from 7 to 36 months. The authors' cumulative experience with this LVAD totals more than 1,506 days of support (greater than 4 years) without evidence of any thromboembolic episodes. These results suggest that this LVAD provides an effective bridge to HTx for extended periods.
Collapse
Affiliation(s)
- M G McGee
- Cullen Cardiovascular Research Laboratories, Texas Heart Institute, Houston 77225-0345
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Allan A, Graham TR, Withington PS, Salih V, Dasse KA, Poirier VL, Lewis CT. Development of a polyurethane percutaneous access device for long-term vascular access. ASAIO Trans 1990; 36:M349-51. [PMID: 2252696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The percutaneous placement of intravascular devices creates a portal for microbial invasion that can result in local infections or septicemia. In nature, resistance to "exist site" infection in percutaneous organs, such as teeth, is prevented by a dense collagen/epithelial barrier. A new percutaneous access device has been developed that incorporates a porous polyurethane "button" at the subdermal level. This device promotes the development of a collagen/epithelial interface, thus inhibiting sinus formation. Twelve percutaneous access devices (PCADS) were implanted in calves; eight devices were utilized for venting of, and hard wire passage to, an implantable left ventricular assist device (LVAD) and served as controls. Four devices were utilized for long-term vascular access. The PCADS remained in situ for 2-127 days (mean 70). Excellent healing was apparent in all cases, and no exit site or catheter related infections occurred. Histologic examination demonstrated fibroblastic in-growth and collagen deposition within the porous polyurethane, which provides a barrier to epithelial migration and firmly anchors the device. These PCADS appear to reduce exit site infections and may improve upon currently available long-term vascular access catheters.
Collapse
Affiliation(s)
- A Allan
- Department of Anaesthetics, London Hospital, UK
| | | | | | | | | | | | | |
Collapse
|
28
|
|
29
|
Macoviak JA, Dasse KA, Poirier VL. Mechanical cardiac assistance and replacement. Cardiol Clin 1990; 8:39-53. [PMID: 2407360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
This article aims not to review the limited and difficult to compare clinical results with mechanical cardiac assist devices. Instead, a practical classification and analysis of these devices is presented, which will afford the clinician insights about when, how, and why to use specific mechanical support.
Collapse
Affiliation(s)
- J A Macoviak
- Washington Heart, Division of Washington Hospital Center, Washington, DC
| | | | | |
Collapse
|
30
|
Dasse KA, Chipman SD, Sherman CN, Levine AH, Frazier OH. Clinical experience with textured blood contacting surfaces in ventricular assist devices. ASAIO Trans 1987; 33:418-25. [PMID: 3314931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- K A Dasse
- Biomedical Research and Development Group, Thermedics, Inc., Woburn, MA 01888-1799
| | | | | | | | | |
Collapse
|
31
|
Daly BD, Dasse KA, Gould KE, Smith TJ, Bousquet GG, Poirier VL, Cleveland RJ. A new percutaneous access device for peritoneal dialysis. ASAIO Trans 1987; 33:664-71. [PMID: 3314937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- B D Daly
- Department of Surgery and Medicine, Tufts University, Boston, MA
| | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Infection continues to pose the major obstacle to long-term percutaneous access. Development of methods to prevent infection or techniques to determine early onset of infection at a time when antibiotic therapy may prove successful would be of enormous value. Our laboratory has been working toward developing and testing a noninvasive semiquantitative swab culture technique (SQ) to monitor percutaneous leads for infection. This technique was found to have a 76% sensitivity having identified 47 of 62 organisms detected by a quantitative tissue culture technique (Q) at the time of system explant. Furthermore, 47 of 61 organisms identified by the SQ technique accurately detected those isolated by the Q techniques. Accordingly, the SQ technique has a 77% specificity. This technique was capable of detecting organisms a median of 14 days prior to overt clinical infection. Prompt initiation of oral antibiotic treatment based on SQ results has doubled system survival compared with untreated systems. Clearly, the SQ technique has proven useful to monitoring percutaneous devices.
Collapse
|
33
|
Abstract
Significant progress has been made in the development of a percutaneous energy transmission system (PETS) designed to provide energy to intracorporeally implanted blood pumps for up to 2 years. The mean survival of our six most recent PETS implantations was 351 +/- 33 days. Four of these were explanted electively after a full year of implantation. Sinus formation around each prosthesis was limited by a biomaterial seal at the sinus termination point. The results support the hypothesis that collagen inhibits epidermal downgrowth. Continued development of systems based on this hypothesis is desirable.
Collapse
|
34
|
Daly BD, Dasse KA, Haudenschild CC, Clay W, Szycher M, Ober NS, Cleveland RJ. Percutaneous energy transmission systems: long-term survival. Trans Am Soc Artif Intern Organs 1983; 29:526-531. [PMID: 6673280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
35
|
Lindsay RL, Chase D, Dasse KA, Burke DJ, Goldberg AH, Ullrick WC. Contractile properties of fast muscle preparations regenerating in slow muscle beds. Experientia 1981; 37:1297-8. [PMID: 7327233 DOI: 10.1007/bf01948371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Mechanical evidence is presented to show that fast muscle tissue regenerating in the bed of a slow muscle, and innervated by the slow muscle nerve, has contractile properties identical to those of a slow muscle regenerating in its own bed. The results do not support the idea that regenerating fast muscles are partially resistant to the transforming effects of a slow nerve.
Collapse
|
36
|
Chase D, Ullrick WC, Dasse KA, Burke DJ, Goldberg AH. Does tenotomy of skeletal muscle alter Z-line width in older animals? Experientia 1981; 37:1300-1. [PMID: 7327235 DOI: 10.1007/bf01948373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
37
|
Abstract
Mechanical properties of rat soleus and plantaris muscles were studied in vitro following tenotomy, denervation, or tenotomy plus denervation, all of 3 wk duration. Controls included muscles from sham-operated animals and from animals with muscle tendons severed but immediately resutured. Results of twitch times, times to peak tension, and times to half-relaxation for 145 muscles clearly showed that the slight increase in muscle speed that occurs in the soleus muscles only is due to severance of the muscle tendon per se and not related to muscle shortening and possible related alterations in muscle spindle activity that occurs in simple tenotomy. Furthermore, any demonstrable mechanical changes that occur with tenotomy or with section and resuturing of the tendon requires the presence of intact innervation. We conclude that, contrary to published opinion, tenotomy does not transform slow contracting muscles into fast contracting muscles and that comments concerning the role of stretch receptors in this postulated transformation are pure conjecture, unsupported by experimental data.
Collapse
|
38
|
Dasse KA, Chase D, Burke D, Goldberg A, Ullrick WC. Repositioning of fast and slow skeletal muscle. J Muscle Res Cell Motil 1981; 2:261-7. [PMID: 7287897 DOI: 10.1007/bf00713265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The origins of the rat fast plantaris and slow soleus muscles were surgically reversed and their fibre types and contractile properties examined in vitro up to 12 weeks post surgery. Muscles in which the origins had been severed and then immediately sutured back in place served as one control group. Unoperated animals served as a second control group. As compared to these groups, no significant differences in the histochemical or mechanical properties of the repositioned muscles were detected. Under the conditions of the experiments, no evidence was obtained to indicate that the intrinsic properties of a muscle could be altered by changing its site of origin and thus its functional environment.
Collapse
|